Pharmacological Evaluation of Trichosanthese Dioica for Management of Alzheimer and Other Dementia Disorders

Investigate the compound’s ability to inhibit acetylcholinesterase, which could contribute to memory enhancement by performing the in-vitro and in-vivo activity. By achieving these objectives, the research will contribute to identifying new, natural therapeutic options for memory enhancement and the treatment of cognitive decline. Additionally, it may pave the way for further studies on the use of Trichosanthese dioica and other herbal compounds in brain health. Pharmacological evaluation of cucurbitacins (B and E) extracted from T.dioica for Antialzhiemer’s approach 3 core Invivo and invitro evaluation study were done for neuroprotective, antioxidant, and acetylcholinesterase inhibition. Both Cucurbitacin B and E exhibited multi-targeted protective effects against Alzheimer’s disease in vitro. They improved cell viability (MTT assay), reduced oxidative stress (DCFDA), decreased inflammatory cytokines (ELISA), and inhibited AChE (Elman’s method). Among the two, Cucurbitacin E consistently showed superior performance, highlighting its promise as a neuroprotective agent for Alzheimer’s therapy.The combination treatments (Donepezil + Cucurbitacin B or E) showed the most effective reduction in ROS, indicating that these compounds might work together to attenuate oxidative stress. The combination groups (CB+Donepezil and CE+ Donepezil) showed slightly lower TNF-α and IL-6 levels than Donepezil alone, Donepezil (78.6%) and Cucurbitacin E (76.4%) significantly restored alternation behavior. Cucurbitacin B (65.8%) also improved performance, though to a lesser extent. Cucurbitacin E emerges as a more potent neuroprotective agent than Cucurbitacin B, offering a strong rationale for its further development as a natural therapeutic lead in Alzheimer’s disease management. This study not only validates the ethno pharmacological use of Trichosanthese dioica but also provides a scientific foundation for the pharmacological advancement of Cucurbitacin based compounds.

Authors

Publication Details

Journal
Journal of Neonatal Surgery
Published
2025-05-06
DOI
https://doi.org/10.63682/jns.v14i18s.5258
Primary Topic
Seed and Plant Biochemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacological Evaluation of Trichosanthese Dioica for Management of Alzheimer and Other Dementia Disorders

Sarika Sharma, Anshu Sharma
Journal of Neonatal Surgery
Seed and Plant Biochemistry
article

Pharmacological Evaluation of Trichosanthese Dioica for Management of Alzheimer and Other Dementia Disorders

Sarika Sharma, Anshu Sharma
article en

Abstract

Investigate the compound’s ability to inhibit acetylcholinesterase, which could contribute to memory enhancement by performing the in-vitro and in-vivo activity. By achieving these objectives, the research will contribute to identifying new, natural therapeutic options for memory enhancement and the treatment of cognitive decline. Additionally, it may pave the way for further studies on the use of Trichosanthese dioica and other herbal compounds in brain health. Pharmacological evaluation of cucurbitacins (B and E) extracted from T.dioica for Antialzhiemer’s approach 3 core Invivo and invitro evaluation study were done for neuroprotective, antioxidant, and acetylcholinesterase inhibition. Both Cucurbitacin B and E exhibited multi-targeted protective effects against Alzheimer’s disease in vitro. They improved cell viability (MTT assay), reduced oxidative stress (DCFDA), decreased inflammatory cytokines (ELISA), and inhibited AChE (Elman’s method). Among the two, Cucurbitacin E consistently showed superior performance, highlighting its promise as a neuroprotective agent for Alzheimer’s therapy.The combination treatments (Donepezil + Cucurbitacin B or E) showed the most effective reduction in ROS, indicating that these compounds might work together to attenuate oxidative stress. The combination groups (CB+Donepezil and CE+ Donepezil) showed slightly lower TNF-α and IL-6 levels than Donepezil alone, Donepezil (78.6%) and Cucurbitacin E (76.4%) significantly restored alternation behavior. Cucurbitacin B (65.8%) also improved performance, though to a lesser extent. Cucurbitacin E emerges as a more potent neuroprotective agent than Cucurbitacin B, offering a strong rationale for its further development as a natural therapeutic lead in Alzheimer’s disease management. This study not only validates the ethno pharmacological use of Trichosanthese dioica but also provides a scientific foundation for the pharmacological advancement of Cucurbitacin based compounds.

Journal of Neonatal SurgeryVol. 14(18S)
Openalex Percentile: Top 88%
Seed and Plant Biochemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Pharmacological Evaluation of Trichosanthese Dioica for Management of Alzheimer and Other Dementia Disorders — Sarika Sharma, Anshu Sharma · Journal of Neonatal Surgery (2025) | TGRS Research Map | TGRS